DVAX - Dynavax Technologies Corporation

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
19.95
-0.45 (-2.21%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close20.40
Open20.40
Bid19.70 x 400
Ask20.15 x 500
Day's Range19.85 - 20.40
52 Week Range3.20 - 24.45
Volume1,096,991
Avg. Volume2,838,273
Market Cap1.21B
Beta0.55
PE Ratio (TTM)-8.24
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Stocks That Turned $3,000 Into $7,300 or More So Far in 2017
    Motley Fool3 days ago

    3 Stocks That Turned $3,000 Into $7,300 or More So Far in 2017

    Here's why Square, Kemet, and Dynavax Technologies have paid off so well for investors this year, and what's on the horizon for each.

  • SmarterAnalyst5 days ago

    Dynavax Technologies Corporation (DVAX) Announces Dosing of First Subject in Phase 1b Study of DV281

    Dynavax Technologies Corporation (NASDAQ:DVAX) announced initiation of dosing in patients with non-small cell lung cancer (NSCLC). This multi-center, open label trial is designed to evaluate safety and identify the optimal dose for a potential expansion phase of the study. The dose escalation study is expected to enroll approximately 24 patients in 5 cohorts with advanced NSCLC that has progressed on previous therapy. Dynavax engineered DV281 specifically for inhalation to facilitate local administration of a TLR9 agonist to lung tumors which are not easily accessible for intratumoral injection.

  • Capital Cube12 days ago

    ETFs with exposure to Dynavax Technologies Corp. : October 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Dynavax Technologies Corp. Here are 5 ETFs with the largest exposure to DVAX-US. Comparing the performance and risk of Dynavax Technologies Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Forbes19 days ago

    Two Techs And Two Biotechs Breaking Out

    Here are two biotech and two tech stocks that are breaking out technically.

  • MarketWatch19 days ago

    Harry Boxer’s four stocks that are breaking out this week

    In focus: Amicus Therapeutics, AVEO Pharmaceuticals, AXT and Dynavax Technologies.

  • Reuters22 days ago

    Deals of the day-Mergers and acquisitions

    (Updates Geely, Bain, Noble Group, Suez; Adds Savola Group, Central Group, OMERS, Laredo Petroleum, Metro) Oct 2 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 ...

  • Motley Fool22 days ago

    Why Dynavax Technologies Corporation Stock Is Rising Today

    Dynavax is reportedly exploring its options regarding vaccine candidate Heplisav-B.

  • TheStreet.com24 days ago

    These 4 Small Biotechs Have Big Upcoming Catalysts

    Zogenix, Flexion, Dynavax and Progenics all have potential upside on these events.

  • Should You Have Dynavax Technologies Corporation’s (DVAX) In Your Portfolio?
    Simply Wall St.24 days ago

    Should You Have Dynavax Technologies Corporation’s (DVAX) In Your Portfolio?

    If you are looking to invest in Dynavax Technologies Corporation’s (NASDAQ:DVAX), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • Reuters24 days ago

    Immunotherapy developer Dynavax explores options for Hepatitis B drug - sources

    A deal for the drug, called Heplisav, which is expected to receive regulatory approval later this year, would give Dynavax a cash infusion that it could use to finance its portfolio of cancer drugs under development. In July, a U.S. Food and Drug Administration panel green-lighted Dynavax's hepatitis B drug, a strong indication that it will be approved. Meanwhile, Dynavax is working on several early-stage clinical trials on drugs that promise to use the body's own immune system to fight cancer.

  • Capital Cube27 days ago

    ETFs with exposure to Dynavax Technologies Corp. : September 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Dynavax Technologies Corp. Here are 5 ETFs with the largest exposure to DVAX-US. Comparing the performance and risk of Dynavax Technologies Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cubelast month

    ETFs with exposure to Dynavax Technologies Corp. : September 15, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Dynavax Technologies Corp. Here are 5 ETFs with the largest exposure to DVAX-US. Comparing the performance and risk of Dynavax Technologies Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • 3 Biotech Stocks I'd Buy Right Now
    Motley Foollast month

    3 Biotech Stocks I'd Buy Right Now

    The outlook for these underappreciated gems is much brighter than their recent performances suggest.

  • Are Options Traders Betting on a Big Move in Dynavax (DVAX) Stock?
    Zackslast month

    Are Options Traders Betting on a Big Move in Dynavax (DVAX) Stock?

    Investors in Dynavax Technologies Corporation (DVAX) need to pay close attention to the stock based on moves in the options market lately.

  • 3 Biotech Stocks That Have Already Quadrupled in 2017
    Motley Foollast month

    3 Biotech Stocks That Have Already Quadrupled in 2017

    None of these companies have a product to sell, but their stock prices have all increased 300% or more this year. Can they keep it up?

  • Benzingalast month

    Dynavax: Buy On Weakness Ahead Of November's PDUFA Date

    Dynavax Technologies Corporation (NASDAQ: DVAX ) is awaiting its tryst with the FDA after a failed attempt in August. Against this backdrop, analyst Cathy Reese of Empire Asset Management Company recommended ...

  • Is It Time To Buy Dynavax Technologies Corporation (DVAX)?
    Simply Wall St.last month

    Is It Time To Buy Dynavax Technologies Corporation (DVAX)?

    Dynavax Technologies Corporation (NASDAQ:DVAX), a pharmaceuticals, biotechnology and life sciences company based in United States, See our latest analysis for DVAX What’s the opportunity in DVAX? The stock seems fairlyRead More...

  • MarketWatch2 months ago

    Harry Boxer: 4 breakout charts to watch

    Two biotech stocks, a gold miner ETF and a technology play make the list.

  • Forbes2 months ago

    Here Are 3 Strong Biotech Stocks In 2017

    After a two-year hiatus, biotech stocks are making a comeback. From the historic May 2009 bottom through the summer of 2015, biotech stocks were one of the strongest groups in the market.

  • Capital Cube2 months ago

    ETFs with exposure to Dynavax Technologies Corp. : August 31, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Dynavax Technologies Corp. Here are 5 ETFs with the largest exposure to DVAX-US. Comparing the performance and risk of Dynavax Technologies Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Dynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube2 months ago

    Dynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Dynavax Technologies Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Dynavax Technologies Corp. – Agenus Inc., Biogen Inc., Idera Pharmaceuticals, Inc., Merck & Co., Inc., Gilead Sciences, Inc., Momenta Pharmaceuticals, Inc., GlaxoSmithKline plc Sponsored ADR, Astrazeneca PLC Sponsored ... Read more (Read more...)

  • Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data
    Zacks2 months ago

    Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data

    Regeneron (REGN) and several other biotech companies reported Q2 earnings while FibroGen hit a 52-week high on promising idiopathic pulmonary fibrosis (IPF) data.

  • 5 Top Stocks for August
    Motley Fool3 months ago

    5 Top Stocks for August

    Don't let the summer heat stop you from buying shares of these five promising businesses.

  • Dynavax Technologies (DVAX) Catches Eye: Stock Adds 11.2% in Session
    Zacks3 months ago

    Dynavax Technologies (DVAX) Catches Eye: Stock Adds 11.2% in Session

    Dynavax Technologies Corporation (DVAX) was a big mover last session, as the company saw its shares rise over 11% on the day.

  • MarketWatch3 months ago

    Dynavax shares plummet 11% on news of delay for FDA decision about its hepatitis B vaccine

    Dynavax Technologies Corp. shares plummeted 11% after the bell Thursday on news that the Food and Drug Administration has requested more information about its post-marketing study of the company's hepatitis ...